Scientists have identified a brand new genetic mechanism that raises the risk of cancer via a domino effect on DNA - with one gene fault triggering a second, cancer-causing mutation. The team, from The Institute of Cancer Research, London, found that some cancer patients inherit a weak point in their DNA which appears to leave one of their chromosomes vulnerable to snapping and becoming mutated.
The researchers hailed the finding, which was published in Nature Genetics, as a "very important discovery" that opens up new avenues for cancer treatment and prevention. The study sheds new light on the causes of multiple myeloma, a type of blood cancer, which affects around 4,700 patients in the UK each year - and could have implications for other types of cancer. It is the first time scientists have found evidence that inheritance of a gene fault can increase the risk of suffering a specific chromosomal mutation - in this case one that can drive development of cancer.
In the study, which was funded by a number of organisations, the DNA of 1,655 patients with myeloma was assessed and compared with people in the general population. This was to explore whether the patients had inherited genetic faults which had increased their risk of developing the disease. They then found that inheritance of a specific DNA range termed CCND1 G870A was associated with an 80% increase in the risk of developing a sub-type of myeloma affecting about a fifth of patients. This sub-type is known to be triggered by a specific chromosomal translocation (a type of DNA breakage and rearrangement) designated by the code t(11;14). The translocation forms a mutant piece of DNA that drives cancer by activating several genes.
Study author Professor Richard Houlston, Professor of Molecular and Population Genetics at the Institute of Cancer Research, said: "It's the first time anyone has identified a specific gene fault that raises the risk of developing a second specific type of DNA damage. Not only is the discovery valuable for our understanding of multiple myeloma, but it also demonstrates the value of studying specific genetic sub-types of cancer, rather than grouping them all together as one disease." Co-author Professor Gareth Morgan, Head of Molecular Haematology at the Institute of Cancer Research and Head of the Myeloma Unit at The Royal Marsden, also commented: "This is a very important discovery, which opens out our understanding of cancer genetics and gives us new avenues for treatment and prevention." He continued to say: "Now that we have found a genetic risk factor for a particular sub-type of multiple myeloma, I'm hopeful we can design more targeted treatments for the people who develop it. In cancer research we tend to group different sub-types together, but this research proves that we need to move away from this approach and investigate sub-types at a molecular level."
Jack
No comments:
Post a Comment